<DOC>
	<DOC>NCT00621868</DOC>
	<brief_summary>The objective of this study is to evaluate the efficacy, safety and pharmacokinetics of ASP1941 in male and female patients with type 2 diabetes mellitus</brief_summary>
	<brief_title>A Phase 2 Study of ASP1941 in Japanese Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Established diagnosis of type 2 diabetes mellitus Fasting serum Cpeptide level &gt; 0.6 ng/mL HbA1c between 7.0 and 10.0% Body Mass Index between 20 and 45 kg/m2 Serum creatinine &gt; upper limit of normal Proteinuria (albumin/creatinine ratio &gt; 300 mg/g) Dysuria and/or urinary tract infection Significant renal, hepatic or cardiovascular diseases Ketosis Hypertension Severe gastrointestinal diseases</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Diabetes Mellitus, Type 2</keyword>
	<keyword>ASP1941</keyword>
</DOC>